MEDIGENE AG NA O.N. news, videos and press releases
For more news please use our advanced search feature.
MEDIGENE AG NA O.N. - More news...
MEDIGENE AG NA O.N. - More news...
-
Medigene – executive interview
- Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform
- Medigene to Present at Upcoming Investor Conferences
- Medigene AG implements announced 2:1 share capital reduction and consolidation of the shares effective August 29, 2024
- Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update
- Medigene AG to Report Half-Year 2024 Financial Results on August 14, 2024
- WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
- Medigene and WuXi Biologics Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
- Medigene to Present at ESMO Congress 2024
- Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China
- Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness
- Medigene Reports Results of Annual General Meeting
- Medigene to Present at the Cell and Gene Therapy In-Depth Focus Summit 2024
- Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumors
- Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
- Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
- Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
- Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
- Medigene to Present at Upcoming Conferences
- Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
- Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
- Medigene AG reports Financial Results and Business Update for Q1 2024
- Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
- Medigene to Present at Upcoming Scientific Conferences
- Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
- Medigene AG Secures European Patent for its iM-TCR Technology
- Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
- Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- Medigene AG to report full year 2023 financial results on March 28, 2024
- Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting
